262 related articles for article (PubMed ID: 34626200)
1. Psychometric evaluation of the Overactive Bladder Questionnaire (OAB-q) for measuring quality of life and clinical implications in Greek patients with overactive bladder.
Kontogiannis S; Athanasopoulos A; Tsagkarakis M; Kontodimopoulos N
Int Urogynecol J; 2022 Nov; 33(11):3035-3043. PubMed ID: 34626200
[TBL] [Abstract][Full Text] [Related]
2. Quality of life in patients with overactive bladder: validation and psychometric properties of the Spanish Overactive Bladder Questionnaire-short Form.
Arlandis S; Ruiz MA; Errando C; Villacampa F; Arumà D; Lizarraga I; Rejas J
Clin Drug Investig; 2012 Aug; 32(8):523-32. PubMed ID: 22741748
[TBL] [Abstract][Full Text] [Related]
3. The validation of the Dutch OAB-q SF: An overactive bladder symptom bother and health-related quality of life short-form questionnaire.
Groenendijk IM; Scheepe JR; Noordhoff TC; Blok BFM
Neurourol Urodyn; 2019 Aug; 38(6):1775-1782. PubMed ID: 31215693
[TBL] [Abstract][Full Text] [Related]
4. Validation of overactive bladder questionnaire (1-week recall version) in medically complex elderly patients with overactive bladder.
Barsdorf AI; Carlsson M; Bushmakin AG; Quinn S; Cappelleri JC; Pleil A
Int Urogynecol J; 2017 Dec; 28(12):1857-1863. PubMed ID: 28378111
[TBL] [Abstract][Full Text] [Related]
5. Test-retest reliability of four questionnaires for patients with overactive bladder: the overactive bladder questionnaire (OAB-q), patient perception of bladder condition (PPBC), urgency questionnaire (UQ), and the primary OAB symptom questionnaire (POSQ).
Matza LS; Thompson CL; Krasnow J; Brewster-Jordan J; Zyczynski T; Coyne KS
Neurourol Urodyn; 2005; 24(3):215-25. PubMed ID: 15747340
[TBL] [Abstract][Full Text] [Related]
6. Psychometric validation of the overactive bladder satisfaction with treatment questionnaire (OAB-SAT-q).
Margolis MK; Fox KM; Cerulli A; Ariely R; Kahler KH; Coyne KS
Neurourol Urodyn; 2009; 28(5):416-22. PubMed ID: 19030182
[TBL] [Abstract][Full Text] [Related]
7. Psychometric validation of an overactive bladder symptom and health-related quality of life questionnaire: the OAB-q.
Coyne K; Revicki D; Hunt T; Corey R; Stewart W; Bentkover J; Kurth H; Abrams P
Qual Life Res; 2002 Sep; 11(6):563-74. PubMed ID: 12206577
[TBL] [Abstract][Full Text] [Related]
8. Symptom bother and health-related quality of life outcomes following solifenacin treatment for overactive bladder: the VESIcare Open-Label Trial (VOLT).
Garely AD; Kaufman JM; Sand PK; Smith N; Andoh M
Clin Ther; 2006 Nov; 28(11):1935-46. PubMed ID: 17213014
[TBL] [Abstract][Full Text] [Related]
9. The psychometric validation of a 1-week recall period for the OAB-q.
Coyne KS; Gelhorn H; Thompson C; Kopp ZS; Guan Z
Int Urogynecol J; 2011 Dec; 22(12):1555-63. PubMed ID: 21739328
[TBL] [Abstract][Full Text] [Related]
10. Validation of a bladder symptom screening tool in women with incontinence due to overactive bladder.
Cardozo L; Staskin D; Currie B; Wiklund I; Globe D; Signori M; Dmochowski R; MacDiarmid S; Nitti VW; Noblett K
Int Urogynecol J; 2014 Dec; 25(12):1655-63. PubMed ID: 24859795
[TBL] [Abstract][Full Text] [Related]
11. Should we use the shorter Thai-version quality of life and symptoms questionnaires in women with overactive bladder?
Bunyavejchevin S; Liao L; Lu SH; Choo MS; Rabbani KJ; Havanond P
J Obstet Gynaecol Res; 2015 Aug; 41(8):1260-5. PubMed ID: 26081949
[TBL] [Abstract][Full Text] [Related]
12. Development and psychometric evaluation of the urgency questionnaire for evaluating severity and health-related quality of life impact of urinary urgency in overactive bladder.
Coyne KS; Sexton CC; Thompson C; Bavendam T; Brubaker L
Int Urogynecol J; 2015 Mar; 26(3):373-82. PubMed ID: 24942375
[TBL] [Abstract][Full Text] [Related]
13. Symptom severity and patient perceptions in overactive bladder: how are they related?
Homma Y; Gotoh M
BJU Int; 2009 Oct; 104(7):968-72. PubMed ID: 19338560
[TBL] [Abstract][Full Text] [Related]
14. Solifenacin for overactive bladder with incontinence: symptom bother and health-related quality of life outcomes.
Garely AD; Lucente V; Vapnek J; Smith N
Ann Pharmacother; 2007 Mar; 41(3):391-8. PubMed ID: 17341526
[TBL] [Abstract][Full Text] [Related]
15. Validation of the Arabic linguistic version of the 8-item overactive bladder questionnaire (OAB-V8).
Al-Shaiji TF; Alkabbani M; El-Nahas AR; Thahir A; Almutairi MF; Al-Terki A
Int Urogynecol J; 2019 Dec; 30(12):2153-2156. PubMed ID: 30788523
[TBL] [Abstract][Full Text] [Related]
16. An overactive bladder symptom and health-related quality of life short-form: validation of the OAB-q SF.
Coyne KS; Thompson CL; Lai JS; Sexton CC
Neurourol Urodyn; 2015 Mar; 34(3):255-63. PubMed ID: 25783168
[TBL] [Abstract][Full Text] [Related]
17. Validation of the urgency questionnaire in Portuguese: A new instrument to assess overactive bladder syndrome.
Moraes RP; Silva JLD; Calado AA; Cavalcanti GA
Int Braz J Urol; 2018; 44(2):338-347. PubMed ID: 29219282
[TBL] [Abstract][Full Text] [Related]
18. Validation of the Overactive Bladder-Bladder Assessment Tool (OAB-BAT): A Potential Alternative to the Standard Bladder Diary for Monitoring OAB Outcomes.
Chapple C; Kelleher C; Siddiqui E; Andrae DA; Johnson N; Payne C; Homma Y; Hakimi Z; Evans C; Lyn N; Kopp Z
Eur Urol Focus; 2021 Sep; 7(5):1176-1183. PubMed ID: 33451958
[TBL] [Abstract][Full Text] [Related]
19. Turkish validation of the overactive bladder symptom score (OABSS) and evaluation of mirabegron treatment response.
Culha MG; Degirmentepe RB; Ozbir S; Cakir SS; Homma Y
Int Urogynecol J; 2019 Dec; 30(12):2121-2126. PubMed ID: 31332467
[TBL] [Abstract][Full Text] [Related]
20. The psychometric validation of the OAB family impact measure (OAB-FIM).
Coyne KS; Matza LS; Brewster-Jordan J; Thompson C; Bavendam T
Neurourol Urodyn; 2010 Mar; 29(3):359-69. PubMed ID: 19274760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]